A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Phase 2 Completed 41 enrolled UCB Biopharma SRL

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Timeline

Start: 2021-04-06
Primary completion: 2025-03-12
Completion: 2025-03-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimekizumab	Monoclonal antibody	—	Subcutaneous

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Summary

Timeline

Drugs

Indications